To help detect kidney damage and follow kidney disorders; sometimes to monitor people who are exposed to cadmium
Were you looking instead for Beta-2 Microglobulin Tumor Marker?
When you have symptoms and signs associated with kidney dysfunction; periodically if you work with cadmium
A blood sample drawn from a vein in your arm; sometimes a random or 24-hour urine sample
Beta-2 microglobulin (B2M) is a protein that is found on the surface of nucleated cells (contain a nucleus) and functions as part of the human immune system. This protein is routinely shed by cells into the blood and is present in most body fluids, with highest levels in the blood, generally lower levels in spinal fluid, and trace levels in urine.
In the kidneys, B2M passes through blood-filtering units called the glomeruli and is then reabsorbed by the renal proximal tubules, structures that reclaim water, proteins, vitamins, minerals, and other vital substances. Normally, only small amounts of B2M are present in the urine, but when the renal tubules become damaged or diseased, B2M concentrations increase due to the decreased ability to reabsorb this protein. When the glomeruli in the kidneys are damaged, they are unable to filter out B2M, so the level in the blood rises.
The beta-2 microglobulin (B2M) test may be used when known physical or suspected kidney damage occurs to distinguish between glomerular and tubular disorders of the kidney. B2M levels will also increase with disorders that involve overactive cell turnover and when the immune system is activated, thus is not diagnostic for a specific disease. With renal failure, it provides additional information about someone's likely prognosis and the health of their kidneys. B2M is measured in the following situations:
Both blood and urine B2M tests may be ordered when a person has signs and symptoms associated with kidney dysfunction and a health practitioner wants to distinguish between disorders that affect the glomeruli and the renal tubules. Some signs and symptoms may include:
A urine test may also be ordered periodically to monitor a person who has had a kidney transplant or to monitor those exposed to high concentrations of cadmium or mercury to detect early kidney dysfunction.
People who have been on dialysis for five years or more may develop dialysis-related amyloidosis (DRA), a condition resulting from the accumulation of excess B2M in the blood and eventually in the bone, joint, tendon (osteoarticular structure) and other body tissues such as heart, lung, and digestive tract. It is primarily diagnosed by tissue or bone biopsy. B2M levels are performed as part of the work-up in addition to imaging studies.
Levels of B2M in the blood vary from low levels to four times the lower limit, and this is considered normal. B2M may be undetectable in the urine.
Increased levels of B2M in the blood and urine indicate that there is a problem but are not diagnostic of a specific disease or condition.
In someone with signs of kidney disease, increased levels of B2M in the blood and low levels in the urine indicate that the disorder is associated with glomeruli dysfunction. If B2M is low in the blood and high in the urine, then it is likely that the person has renal tubule damage or disease. Also, B2M levels correlate with risk of cardiovascular disease (CVD) and with cause of death in patients with kidney disease or on dialysis.
In a person who has been on long-term dialysis, an increase in B2M is associated with dialysis-related amyloidosis.
Increases in urine B2M in a person with a kidney transplant may indicate early kidney rejection.
Increases in someone who is exposed to high levels of cadmium or mercury may indicate early kidney dysfunction.
No, the test requires specialized equipment and training and is not available in every laboratory. Your blood or urine may be sent to a reference laboratory.
That depends on the laboratory performing the test. Since your sample may be sent to a reference laboratory for testing, it may take several days for results to be available.
In most cases, the sample tested will be dictated by the reason that the test is being performed. It may be necessary to do a blood test, a urine test, or both together. In certain neurologic situations, cerebrospinal fluid (CSF) may also be tested (see the Beta-2 Microglobulin Tumor Marker test article). The results are not generally interchangeable.
Generally, no. It means that you may have some early kidney damage that affects your renal tubules. If you work with or suspect that you have been exposed to cadmium or mercury, then your doctor will order specific tests for cadmium or mercury in your blood and/or urine (see the article on Heavy Metals).
Conditions associated with an increased rate of cell production or destruction, severe infections, viral infections such as CMV (cytomegalovirus), and some conditions that activate the immune system, such as inflammatory conditions and autoimmune disorders, can cause increases in beta-2 microglobulin levels, but the test is not typically ordered to monitor these conditions.
Drugs such as lithium, cyclosporine, cisplatin, carboplatin, gentamicin, interferon-α, and aminoglycoside antibiotics can increase B2M blood and/or urine concentrations.
Increases in blood and urine B2M can be seen with certain cancers, including multiple myeloma, leukemia, and lymphoma. When there is central nervous system involvement, increased B2M may also be found in the cerebrospinal fluid (see the Beta-2 Microglobulin Tumor Marker article). B2M may also be present in infectious and cerebrovascular disorders. In cases of HIV, an inverse correlation between B2M and CD4+ T-lymphocytes has been shown to mark disease progression.
B2M is increased in patients with peripheral artery disease (PAD).
Recent nuclear medicine procedures and radiographic contrast media can affect test results.
In people with kidney disease who are undergoing dialysis, B2M can form long protein chains that can be deposited in joints and tissues, causing stiffness and pain. This condition is called B2M dialysis-associated amyloidosis.
Sources Used in Current Review
2017 review performed by Rita Khoury, MD, DABCC, FACB, Laboratory Director, Aculabs, Inc.
Surovi Hazarika, Brian H. Annex. (2017) Biomarkers and Genetics in Peripheral Artery Disease. Clinical Chemistry Jan 2017, 63 (1) 236-244.
Giuseppe Coppolino, Davide Bolignano, Laura Rivoli, et al. (2014) Tumour Markers and Kidney Function: A Systematic Review. BioMed Research International Volume 2014 (2014), Article ID 647541, 9 pages.
Sedighi O, Abediankenari S, Omranifar B. (2015) Association Between Plasma Beta-2 Microglobulin Level and Cardiac Performance in Patients With Chronic Kidney Disease. Nephro-urology Monthly. 2015;7(1):e23563. doi:10.5812/numonthly.23563.
Zeng X, Hossain D, Bostwick DG, Herrera GA, Ballester B, et al. (2014) Urinary β2-Microglobulin is a Sensitive Indicator for Renal Tubular Injury. SAJ Case Rep 1: 103. doi: 10.18875/2375-7043.1.103.
Anita Basu, MD, FACP; Vecihi Batuman, MD, FASNl Reynaldo Matute, MD, et al. (2017) Dialysis-Related Beta-2m Amyloidosis. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed May 2017.
Sources Used in Previous Reviews
Pagana, K. D. & Pagana, T. J. (© 2007). Mosby's Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 155-156.
Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 742-743.
Basu, A. et. al. (Updated 2008 February 22). Amyloidosis, Beta2M (Dialysis-Related) eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed August 2009.
Holmes, R. et. al. (Updated: 2009 July 30). Amyloidosis, Overview. eMedicine [On-line information]. Available online at http://emedicine.medscape.com/article/335414-overview. Accessed August 2009.
(Updated 2008 September). Renal Function Markers - Kidney Disease. ARUP Consult [On-line information]. Available online at http://www.arupconsult.com/Topics/RenalDz/RenalFunctionMarkers.html?client_ID=LTD. Accessed August 2009.
(© 1995–2009). Overview: Beta-2 Microglobulin (B-M), Urine. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/300243. Accessed August 2009.
(© 1995–2009). Overview: Beta-2-Microglobulin (Beta-2-M), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/9234. Accessed August 2009.
(2006 May). Amyloidosis and Kidney Disease. National Kidney and Urologic Diseases Information Clearinghouse [On-line information]. Available online at http://kidney.niddk.nih.gov/kudiseases/pubs/amyloidosis/. Accessed August 2009.
Basu, A. et. al. (Updated 2012 August 2). Dialysis-Related Beta-2m Amyloidosis. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/246542-overview. Accessed June 2013.
Gooptu, M. and Scarpaci, A. (Updated 2012 April 6). Beta2-Microglobulin. Medscape Reference [On-line information]. Available online at http://emedicine.medscape.com/article/2086864-overview. Accessed June 2013.
Beta-2-Microglobulin (Beta-2-M), Serum. Mayo Clinic Mayo Medical Laboratories [On-line information]. Available online at http://www.mayomedicallaboratories.com/test-catalog/Overview/9234. Accessed June 2013.
Liabeuf, S. (2012 August 15). Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney International (2012) 82, 1297–1303 Abstract [On-line information]. Available online at http://www.nature.com/ki/journal/v82/n12/abs/ki2012301a.html. Accessed June 2013.
(Updated 2010 September 9). Amyloidosis and Kidney Disease. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [On-line information]. Available online at http://kidney.niddk.nih.gov/kudiseases/pubs/amyloidosis/. Accessed June 2013.
Winchester, J. (2005 July). Novel Changes in Beta2-Microglobulin in Dialysis Patients. Clinical Chemistry v 51 (7) 1089-1090 [On-line information]. Available online at http://www.clinchem.org/content/51/7/1089.full. Accessed June 2013.
Pagana, K. D. & Pagana, T. J. (© 2011). Mosby's Diagnostic and Laboratory Test Reference 10th Edition: Mosby, Inc., Saint Louis, MO. Pp 680-682.
Tietz Textbook of Clinical Chemistry and Molecular Diagnostics. Burtis CA, Ashwood ER, Bruns DE, eds. 4th edition, St. Louis: Elsevier Saunders; 2006, pg 555.
Rao LV, Pechet L, Jenkins A, et al. Laboratory tests, in Wallach's Interpretation of Diagnostic Tests, 9th ed. (2011) Williamson MA, Snyder ML, eds. Lippincott Williams & Wilkins. Chapter 2.